Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. - Wikidata - awgldk - TriplyDB

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

http://www.wikidata.org/entity/Q33945734

about

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation Serum concentrations of Erlotinib at a dose of 25 mg daily.Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Genetic modifiers of EGFR dependence in non-small cell lung cancer.Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Acquired resistance to TKIs in solid tumours: learning from lung cancer.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer.Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.Precision, accuracy, and resolution-Dose selection of oral anticancer agents.Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis

P2860

Q26751274-8263A68D-95EC-4AD4-A8D1-991BBBC09440 Q27680966-9E8FCDC3-08BE-4245-ABCD-42E990098310 Q30850656-4719BFA8-F889-4939-B2A9-EB56C0DC54E0 Q33822521-5ECD5F2E-888A-447F-961F-E9C48DED69FD Q33955857-4D144017-51D6-4D3F-BB4A-C850FA8AB4BD Q34097177-1A097E7C-1CB1-460C-82F6-F83CCB117798 Q34773458-0E9AC343-7027-4A0C-9729-A73E2ED305B6 Q34832117-88955893-063E-4ECA-A15F-AD590A0DF347 Q35146927-C50F3692-816E-42BF-BB27-5632AF1C3655 Q35591358-777A3C33-8F75-44DC-9FF3-1D6EE2A24A5E Q35894882-98514A3D-4967-4CF7-A7DC-4686A29E9C8E Q36406541-EDA06139-F969-4B22-BA90-CE45BA833814 Q36491122-E17E2A58-87D5-491E-9B2C-50E6835C26BF Q36956272-C6AD7F3C-5334-438B-8E8D-82EB5B514185 Q37354067-95B63501-BD39-47E9-9532-3AC70EFDC969 Q37541523-15535D41-1F9F-4204-8328-480F2C975FA6 Q37709182-7BC78FA6-7957-4D1E-BFC2-F5A67961AD6D Q38190857-265EF94E-A47E-488B-86D6-62113A415E03 Q38224967-9697DC81-7478-4CE7-8B6C-0FF495B7F2DF Q38653663-483CDE3C-8DF6-4DD4-8341-65C105D70A50 Q38927992-AD976520-3657-4602-BB05-6DF9C47607D1 Q39004424-63147D6E-B2C5-4903-8288-EB236593F664 Q39034201-42754566-A2C0-441C-B960-D5A148619E0A Q39179464-53EB0EB7-981B-4FC5-9CA6-872F0F14AE2F Q40386800-A0A0558F-DB0D-4904-AD37-3682D5F6A4FC Q40480137-F840B11A-3249-49F0-AAD2-17738843AC4B Q40485092-C69292A6-EADC-45E3-85FE-13BC5C6BCBFC Q41812546-185B7DF1-5BD0-49FB-AFEB-D9440DFB79CE Q43515674-0A990FBC-825E-4A13-9159-1D99D7EA5ED5 Q54115504-EF74300B-F86E-4487-9514-E41E1861D190 Q54403335-6E499901-FB9A-4D1F-BFBE-0A91F6E5DC04 Q54467809-3305813B-0F5F-4D61-8858-59E143BBE46F Q54520157-F671C312-A1FC-4763-8019-B2924247C21D Q54531638-6AEC065B-2BD1-4795-8A4E-AF0D0AEE010B Q58803156-928684A1-12CC-49B8-9E18-254B30E927F2

P2860

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

http://www.wikidata.org/entity/Q33945734

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@ast

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@en

type

label

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@ast

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@en

prefLabel

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@ast

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@en

P1433

Q33945734-57CF59D5-AD48-457A-A754-3C674C53D451

P1476

Q33945734-7C728ADE-12D5-49D3-9B35-5A5941AAE536

P2093

Q33945734-0B2CA709-69AC-41B4-9F0F-5FE7C368325B

Q33945734-1658C1FD-E457-4D51-98BD-810E73404A11

Q33945734-2A638128-7C96-4628-9192-98230C93DDC1

Q33945734-4AEFE16E-D87A-4011-B94F-ACE2AB2294F5

Q33945734-5DC81B6E-51EE-4B00-8461-6A36D8EC9A21

Q33945734-7BE48084-83EF-4E36-9C1A-66350015AD3C

Q33945734-844C39FA-9ECF-41FF-86D1-56494ECB73F0

Q33945734-8C8A1443-3966-47A1-8E5B-093D59A1EA84

Q33945734-B3D6724A-94D8-44C2-A1E6-246FB474146E

Q33945734-D22594A1-C197-4656-A76F-CF146C0DF10B

P2860

Q33945734-0089C1C6-6C78-4E08-B45E-A751C9301E04

Q33945734-04A9F523-9119-4E89-B840-332BE627799A

Q33945734-054F5B7D-F193-4419-ACD6-F69283C73D5E

Q33945734-128448D5-BD9B-4B11-9CA5-D09BEC35F2A4

Q33945734-21F502AF-9DFA-485A-A01A-BF070958DB42

Q33945734-220AF915-8AC8-4B53-B956-67D4098192F3

Q33945734-22E54829-8F1B-4302-A320-3EBDF3ECFF0F

Q33945734-25397D1B-BD8B-40EB-9D30-21B351325ABE

Q33945734-327107DA-B753-42F4-8ED0-B364CD3F2124

Q33945734-39DCDE38-1836-4506-8E99-748D591CFD89

P304

Q33945734-72AF2710-3E8E-4DF4-8080-9BD344ED0756

P31

Q33945734-A78F397E-BB99-4867-8CF2-50F247C694B6

P356

Q33945734-81BC246B-1082-4E5B-8810-99CE133CA547

P433

Q33945734-2D5A382F-FECC-411D-8009-9E5ABCF7AF6F

P478

Q33945734-F4355CB1-3AB0-46FD-8E5E-4F34FC641792

P50

Q33945734-D24B1BE9-3F24-4E6F-8D2A-68D4B273DF8C

P577

Q33945734-D59C66B7-EDB2-45EB-9005-2C6F0350A157

P5875

Q33945734-24BB0F6F-E93D-4F79-9B69-1DE2DE87587D

P698

Q33945734-2E1610B7-060C-4EA0-9054-BFB60C789516

P932

Q33945734-94E82EA1-757E-428A-980E-8B7EA093D45C

P356

JTO.0B013E3181DD1386

P1433

Journal of Thoracic Oncology

P1476

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

@en

P2093

Beow Y Yeap

http://www.w3.org/2001/XMLSchema#string

Daniel B Costa

http://www.w3.org/2001/XMLSchema#string

Daniel G Tenen

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Jeremy L Warner

http://www.w3.org/2001/XMLSchema#string

Kelly Bodio

http://www.w3.org/2001/XMLSchema#string

Mark G Kris

http://www.w3.org/2001/XMLSchema#string

Mark S Huberman

http://www.w3.org/2001/XMLSchema#string

Michelle W Lau

http://www.w3.org/2001/XMLSchema#string

Susumu Kobayashi

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

1048-1053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E3181DD1386

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44639255

http://www.w3.org/2001/XMLSchema#string

P698

20512075

http://www.w3.org/2001/XMLSchema#string

P932

2893286

http://www.w3.org/2001/XMLSchema#string